Seminari di Ematologia Oncologica - Società Italiana di Ematologia

CHOP and 3x DHAP plus Rituximab followed by a
high dose ARA-C containing myeloablative regimen
and autologous stem cell transplantation (ASCT) is
superior to 6 courses CHOP plus Rituximab followed
by myeloablative radiochemotherapy and ASCT in
mantle cell lymphoma: results of the MCL younger
trial of the European Mantle Cell Lymphoma Network
(MCL net) (Abstract). Blood. 2010; 116: 110.
53. Lefrère F, Delmer A, Levy V, Delarue R, Varet B, Hermine
O. Sequential chemotherapy regimens followed by
high-dose therapy with stem cell transplantation in
mantle cell lymphoma: an update of a prospective
study. Haematologica. 2004; 89: 1275-6.
54. Dreyling M, Lenz G, Hoster E, Van Hoof A,
Gisselbrecht C, Schmits R, et al. Early consolidation
by myeloablative radiochemotherapy followed by
autologous stem cell transplantation in first remission
significantly prolongs progression-free survival in mantle-cell
lymphoma: results of a prospective randomized
trial of the European MCL Network. Blood. 2005;
105: 2677-84.
55. Dreyling MH, Hoster E, Van Hoof A, Metzner B,
Gisselbrecht C, Pfreundschuh M, et al. Early consolidation
with myeloablative radiochemotherapy followed
by autologous stem cell transplantation in first
remission in mantle cell lymphoma: long term follow
up of a randomized trial of the (Abstract). Blood. 2008;
112: 769.
56. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly
H, et al. RCHOP and RDHAP followed by autologous
stem cell transplantation (ASCT) in mantle cell lymphoma
(MCL): final results of a phase II study from
the GELA (Abstract). Blood. 2008; 112: 581.
57. Magni M, Di Nicola M, Carlo-Stella C, Matteucci P,
Devizzi L, Tarella C, et al. High-dose sequential
chemotherapy and in vivo rituximab-purged stem cell
autografting in mantle cell lymphoma: a 10-year
update of the R-HDS regimen. Bone Marrow
Transplant. 2009; 43: 509-11.
58. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR,
Hagemeister FB, Pro B, et al. High rate of durable
remissions after treatment of newly diagnosed
aggressive mantle-cell lymphoma with rituximab
plus hyper-CVAD alternating with rituximab plus highdose
methotrexate and cytarabine. J Clin Oncol. 2005;
23: 7013-23.
59. Romaguera JE, Fayad LE, McLaughlin P, Pro B,
Rodriguez A, Wang M, et al. Phase I trial of bortezomib
in combination with rituximab-HyperCVAD
alternating with rituximab, methotrexate and cytarabine
for untreated aggressive mantle cell lymphoma.
Br J Haematol. 2010; 151: 47-53.
60. Epner EM, Unger J, Miller T, Rimzsa L, Spier C,
Leblanc M, et al. A multi center trial of hyperCVAD +
Rituxan in patients with newly diagnosed mantle cell
lymphoma (Abstract). Blood. 2007; 110: 387.
61. Lefrère F, Delmer A, Suzan F, Levy V, Belanger C,
Linfoma mantellare
Djabarri M, et al. Sequential chemotherapy by CHOP
and DHAP regimens followed by high-dose therapy
with stem cell transplantation induces a high rate of
complete response and improves event-free survival
in mantle cell lymphoma: a prospective study.
Leukemia. 2002; 16: 587-93.
62. Forstpointner R, Dreyling M, Repp R, Hermann S,
Hänel A, Metzner B, et al. The addition of rituximab
to a combination of fludarabine, cyclophosphamide,
mitoxantrone (FCM) significantly increases the
response rate and prolongs survival as compared with
FCM alone in patients with relapsed and refractory
follicular and mantle cell lymphomas: results of a
prospective randomized study of the German Low-
Grade Lymphoma Study Group. Blood. 2004; 104:
3064-71.
63. de Guibert S, Jaccard A, Bernard M, Turlure P,
Bordessoule D, Lamy T. Rituximab and DHAP followed
by intensive therapy with autologous stem-cell
transplantation as first-line therapy for mantle cell lymphoma.
Haematologica. 2006; 91: 425-6.
64. Meusers P, Engelhard M, Bartels H, Binder T, Fülle
HH, Görg K, et al. Multicentre randomized therapeutic
trial for advanced centrocytic lymphoma: anthracycline
does not improve the prognosis. Hematol
Oncol. 1989; 7: 365-80.
65. Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella
C, Venco A, et al. Patterns of survival in mantle cell
lymphoma. Ann Oncol. 1995; 6: 257-62.
66. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer
U, Fey MF, et al. Effect of single-agent rituximab given
at the standard schedule or as prolonged treatment
in patients with mantle cell lymphoma: a study
of the Swiss Group for Clinical Cancer Research
(SAKK). J Clin Oncol. 2005; 23: 705-11.
67. Rummel MJ, Niederle N, Maschmeyer G, Banat A, von
Gruenhagen U, Losem C, et al. Bendamustine plus
Rituximab is superior in respect of progression free
survival and CR rate when compared to CHOP plus
Rituximab as first-line treatment of patients with
advanced follicular, indolent, and mantle cell lymphomas:
final results of a randomized phase III study
of the StiL (Study Group Indolent Lymphomas,
Germany) (Abstract). Blood. 2009; 114: 405.
68. Unterhalt M, Herrmann R, Tiemann M, Parwaresch R,
Stein H, Trümper L, et al. Prednimustine, mitoxantrone
(PmM) vs cyclophosphamide, vincristine, prednisone
(COP) for the treatment of advanced low-grade non-
Hodgkin’s lymphoma. German Low-Grade Lymphoma
Study Group. Leukemia. 1996; 10: 836-43.
69. Forstpointner R, Unterhalt M, Dreyling M, Böck HP,
Repp R, Wandt H, et al. Maintenance therapy with
rituximab leads to a significant prolongation of
response duration after salvage therapy with a combination
of rituximab, fludarabine, cyclophosphamide,
and mitoxantrone (R-FCM) in patients with recurring
and refractory follicular and mantle cell lymphomas:
43